Analysts Expect Athenex Inc (NASDAQ:ATNX) to Post -$0.44 EPS
Brokerages expect that Athenex Inc (NASDAQ:ATNX) will report earnings of ($0.44) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Athenex’s earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.40). Athenex reported earnings per share of ($0.58) during the same quarter last year, which would suggest a positive year over year growth rate of 24.1%. The firm is scheduled to announce its next earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Athenex will report full-year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($1.94) to ($1.51). For the next year, analysts expect that the business will post earnings of ($1.31) per share, with EPS estimates ranging from ($2.03) to ($0.63). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Athenex.
Athenex (NASDAQ:ATNX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.08). Athenex had a negative net margin of 189.86% and a negative return on equity of 96.55%. The firm had revenue of $25.31 million for the quarter, compared to analyst estimates of $19.55 million.
In related news, major shareholder Perceptive Advisors Llc acquired 100,000 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average cost of $12.71 per share, with a total value of $1,271,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephanie A. Davis acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $180,000.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at $180,000. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 318,210 shares of company stock worth $5,111,581. 18.80% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its stake in Athenex by 913,400.0% in the first quarter. BNP Paribas Arbitrage SA now owns 9,135 shares of the company’s stock valued at $112,000 after buying an additional 9,134 shares during the period. Prudential Financial Inc. bought a new stake in Athenex during the fourth quarter worth $147,000. Virginia Retirement Systems ET AL bought a new stake in Athenex during the first quarter worth $158,000. Metropolitan Life Insurance Co. NY grew its holdings in Athenex by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,245 shares of the company’s stock worth $181,000 after buying an additional 11,125 shares in the last quarter. Finally, Private Advisor Group LLC grew its holdings in Athenex by 6.2% during the fourth quarter. Private Advisor Group LLC now owns 17,091 shares of the company’s stock worth $217,000 after buying an additional 991 shares in the last quarter. 31.21% of the stock is currently owned by institutional investors.
Shares of ATNX stock traded down $0.43 during mid-day trading on Friday, reaching $19.06. 601,134 shares of the stock traded hands, compared to its average volume of 690,459. The business has a fifty day moving average price of $18.04. Athenex has a 1-year low of $9.38 and a 1-year high of $21.11. The stock has a market capitalization of $1.31 billion, a P/E ratio of -13.24 and a beta of -0.29. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.85 and a current ratio of 2.22.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.
Read More: Trading signals using Bollinger bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.